An official website of the United States government
Here's how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Brought to you by the Council of the Inspectors General on Integrity and Efficiency
Federal Reports
Report Date
Agency Reviewed / Investigated
Report Title
Type
Location
Department of Agriculture
Rural Housing Service's Controls over Originating and Closing Single Family Housing Direct Loans - Interim Report
Independent Evaluation of the U.S. Equal Employment Opportunity Commission’s Compliance with Provisions of the Federal Information Security Modernization Act of 2014 (FISMA)
We found that EEOC generally had sound information security controls for its Information Security Program and has implemented security controls in all seven DHS Inspector General (IG) FISMA Reporting Metrics. Based on our audit work, we concluded that the EEOC’s Information Security Program is generally compliant with the FISMA legislation and applicable Office of Management and Budget (OMB) guidance and the security controls tested demonstrated operating effectiveness.
Manufacturers with rebate agreements are required to report all of their covered outpatient drugs to the Medicaid Drug Rebate Program (Medicaid rebate program). CMS calculates rebate amounts using manufacturer reported pricing and classification data. Congress asked OIG to evaluate the accuracy of manufacturer reported data in the Medicaid rebate program, and CMS's oversight of that data. The Food and Drug Administration's (FDA's) marketing categories, which also are manufacturer reported, can be used to help determine whether a drug is classified as an innovator, e.g., brand name, or noninnovator, e.g., generic, product, for the purposes of calculating Medicaid rebates. Innovator products are generally subject to higher base rebate amounts. Manufacturers are required to pay an additional, inflation adjusted rebate if a drug's price increases faster than inflation. When information provided by drug manufacturers is incorrect or missing, State Medicaid agencies may not be able to collect all appropriate rebates.
Council of the Inspectors General on Integrity and Efficiency
Report Description
The Inspector General Empowerment Act of 2016 mandated that the Council of the Inspectors General on Integrity and Efficiency (CIGIE) conduct an analysis of critical issues that involve the jurisdiction of more than one individual federal agency. In response, we have consulted within the Inspector General community to determine six high-impact issues where coordination and collaboration would continue to be most beneficial.
